New cholesterol drug could prevent thousands of heart attacks, study suggests

NCT ID NCT07214857

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study used national health survey data to estimate how many US adults with high cholesterol might be eligible for a new drug called inclisiran. Researchers also calculated how many heart attacks and strokes could be prevented over 10 years if these patients took the drug. The study did not give inclisiran to anyone—it was a computer-based analysis using existing health records.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inclisiran
What this could lead to: If the estimates are accurate, this could show that inclisiran might prevent thousands of heart attacks and strokes in eligible patients.
What could go wrong: This is a modeling study based on surveys, not a clinical trial testing the drug directly. Real-world results may differ, and inclisiran's actual effectiveness and safety are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease cardiovascular disorder diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.